Stryker (NYSE:SYK) VP Sells $1,394,417.28 in Stock

Stryker Corporation (NYSE:SYK) VP Robert Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stryker Price Performance

Shares of Stryker stock traded down $1.90 on Friday, hitting $305.73. The company’s stock had a trading volume of 6,064,642 shares, compared to its average volume of 2,296,474. The company has a market capitalization of $117.21 billion, a price-to-earnings ratio of 35.39, a price-to-earnings-growth ratio of 1.93 and a beta of 0.80. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The firm has a fifty day moving average price of $322.61 and a 200-day moving average price of $348.45.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the business posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.2%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is 40.74%.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Brighton Jones LLC boosted its position in shares of Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares during the period. Schnieders Capital Management LLC. acquired a new position in Stryker during the second quarter worth $205,000. Marshall Wace LLP lifted its stake in Stryker by 107.9% during the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after purchasing an additional 77,831 shares in the last quarter. Nebula Research & Development LLC acquired a new position in Stryker during the second quarter worth $219,000. Finally, HUB Investment Partners LLC acquired a new position in Stryker during the second quarter worth $253,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on SYK. Robert W. Baird set a $385.00 price target on shares of Stryker in a research report on Friday, May 1st. Wells Fargo & Company cut their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Needham & Company LLC decreased their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. UBS Group lowered their target price on Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a report on Tuesday, March 17th. Finally, BTIG Research cut their price target on Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a report on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $395.48.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.